Clarithromycin is currently one of the antibiotics used for eradication of Helicobacter pylori. However, reports of H. pylori resistance to this antibiotic are increasing worldwide.

Bismuth compounds have been used for centuries in medicine. The discovery of H. pylori in 1983 led to renewed interest in bismuth compounds, because these were found to successfully treat the infection in combination with antibiotics.

Some bacteria may help protect against the development of a type of esophageal cancer, known as adenocarcinoma, according to a new review of the medical literature. These bacteria, which are called Helicobacter pylori, live in the stomachs of humans.

The most popular treatment for H pylori is triple therapy but resistance to Clarithromycin is reducing its effectiveness. Courses using four drugs have been known to be more successful but are used less popular because of their side-effects. While, what is the best way for treating H pylori-related diseases.

Helicobacter pylori is one tough bug. It can survive in the human stomach, a zone with a pH somewhere between that of lemon juice and battery acid. Now researchers have discovered how an H. pylori toxin gets into cells, a feat that helps the bacterium live in one of the most inhospitable environments in the body.

The Gram negative bacterium H pylori is involved in the pathogenesis of several gastrointestinal diseases, ultimately leading to gastric carcinoma. Adhesion of the bacteria to the gastric mucosa is an essential step for colonization and infection.

Cytotoxin-associated gene A protein (CagA) from type I H.pylori has been proved by epidemiological and experimental studies to be closely associated with the H.pylori induced gastric diseases, especially gastric cancer.

New immunization methods offer long-term protection against H. pylori in humans and may contribute to a possible ulcer vaccine in the future say researchers from the University of California, Davis. They report their findings in the July 2007 journal Infection and Immunity.